SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Antibody Persistence After Primary SARS-CoV-2 Infection and Protection Against Future Variants Including Omicron in Adolescents: National, Prospective Cohort Study.

Aiano, F; Ireland, G; Baawuah, F; Beckmann, J; Okike, IO; Ahmad, S; Garstang, J; Brent, AJ; Brent, B; Borrow, R; et al. Aiano, F; Ireland, G; Baawuah, F; Beckmann, J; Okike, IO; Ahmad, S; Garstang, J; Brent, AJ; Brent, B; Borrow, R; Linley, E; Ho, S; Carr, C; Zambon, M; Poh, J; Warrener, L; Amirthalingam, G; Brown, KE; Ramsay, ME; Hoschler, K; Ladhani, SN (2023) Antibody Persistence After Primary SARS-CoV-2 Infection and Protection Against Future Variants Including Omicron in Adolescents: National, Prospective Cohort Study. Pediatr Infect Dis J, 42 (6). pp. 496-502. ISSN 1532-0987 https://doi.org/10.1097/INF.0000000000003890
SGUL Authors: Ladhani, Shamez Nizarali

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (617kB) | Preview
[img] Microsoft Word (.docx) (Supplemental Digital Content) Published Version
Available under License Creative Commons Attribution.

Download (17kB)

Abstract

BACKGROUND: Antibodies are a measure of immunity after primary infection, which may help protect against further SARS-CoV-2 infections. They may also provide some cross-protection against SARS-CoV-2 variants. There are limited data on antibody persistence and, especially, cross-reactivity against different SARS-CoV-2 variants after primary infection in children. METHODS: We initiated enhanced surveillance in 18 secondary schools to monitor SARS-CoV-2 infection and transmission in September 2020. Students and Staff provided longitudinal blood samples to test for variant-specific SARS-CoV-2 antibodies using in-house receptor binding domain assays. We recruited 1189 students and 1020 staff; 160 (97 students, 63 staff) were SARS-CoV-2 nucleocapsid-antibody positive at baseline and had sufficient serum for further analysis. RESULTS: Most participants developed sustained antibodies against their infecting [wild-type (WT)] strain as well as cross-reactive antibodies against the Alpha, Beta and Delta variants but at lower titers than WT. Staff had significantly lower antibodies titers against WT as cross-reactive antibodies against the Alpha, Beta and Delta variants than students (all P < 0.01). In participants with sufficient sera, only 2.3% (1/43) students and 17.2% (5/29) staff had cross-reactive antibodies against the Omicron variant; they also had higher antibody titers against WT (3042.5; 95% confidence interval: 769.0-12,036.2) than those who did not have cross-reactive antibodies against the Omicron variant (680.7; 534.2-867.4). CONCLUSIONS: We found very high rates of antibody persistence after primary infection with WT in students and staff. Infection with WT induced cross-reactive antibodies against Alpha, Beta and Delta variants, but not Omicron. Primary infection with WT may not be cross-protective against the Omicron variant.

Item Type: Article
Additional Information: Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Keywords: Child, Adolescent, Humans, SARS-CoV-2, Prospective Studies, COVID-19, Antibodies, Viral, Antibodies, Neutralizing, Humans, Antibodies, Viral, Prospective Studies, Adolescent, Child, Antibodies, Neutralizing, COVID-19, SARS-CoV-2, school, antibody, SARS-CoV-2, 1114 Paediatrics and Reproductive Medicine, 1117 Public Health and Health Services, Pediatrics
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: Pediatr Infect Dis J
ISSN: 1532-0987
Language: eng
Dates:
DateEvent
1 June 2023Published
1 March 2023Published Online
12 January 2023Accepted
Publisher License: Creative Commons: Attribution 4.0
PubMed ID: 36916856
Web of Science ID: WOS:000991916200020
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/115524
Publisher's version: https://doi.org/10.1097/INF.0000000000003890

Actions (login required)

Edit Item Edit Item